Alefacept is a lymphocyte function-associated antigen-3/IgG1 fusion protein that inhibits T-cells by antagonizing CD2, which has been developed and launched by Biogen for the potential treatment of psoriasis. In February 2003, Biogen launched alefacept in the US for use in adults with moderate-to-severe chronic plaque psoriasis, and by March 2003, the company was preparing for psoriasis trials to commence in Japan by the end of December 2003.
|Number of pages||6|
|Journal||Current Opinion in Investigational Drugs|
|Publication status||Published - 1 May 2003|
- Anti-Inflammatory Agents, Non-Steroidal
- Antigens, CD58
- Recombinant Fusion Proteins
- Technology, Pharmaceutical